Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the International Society of Renal Nutrition and Metabolism

Kidney International

Volumn 84, Issue 6, 2013, Pages 1096-1107

  Ikizler, T Alp ^a   Cano, Noel J ^b   Franch, Harold ^c   Fouque, Denis ^d   Himmelfarb, Jonathan ^e   Kalantar Zadeh, Kamyar ^f   Kuhlmann, Martin K ^g   Stenvinkel, Peter ^h   Terwee, Pieter ⁱ   Teta, Daniel ^j   Wang, Angela Yee Moon ^k   Wanner, Christoph ^l  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

^l UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

dialysis; malnutrition; metabolism; nutrition; supplementation

Indexed keywords

ANTIINFLAMMATORY AGENT; APPETITE STIMULANT; MEGESTROL ACETATE; NANDROLONE DECANOATE; RECOMBINANT GROWTH HORMONE; STEROID;

CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; DIETARY INTAKE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXERCISE; HORMONE DEFICIENCY; HUMAN; HYPOGONADISM; IMPOTENCE; INFLAMMATION; INTRADIALYTIC PARENTERAL NUTRITION; METABOLIC ACIDOSIS; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN ENERGY WASTING; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; WASTING SYNDROME;

ANABOLIC AGENTS; APPETITE STIMULANTS; COMBINED MODALITY THERAPY; COMORBIDITY; DIETARY SUPPLEMENTS; ENERGY METABOLISM; EXERCISE; HUMANS; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84876713791     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.147     Document Type: Review

References (161)

1. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50: 343-357.
2. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994; 24: 1002-1009.
3. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398.
4. Kalantar-Zadeh K, Block G, McAllister CJ et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
5. K/DOQI) NKFKDOQIN. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35: S1-140.
6. Carrero JJ, Stenvinkel P, Cuppari L et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement From the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 2013; 23: 77-90.
7. Johansen KL, Painter PL, Sakkas GK et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 2006; 17: 2307-2314.
8. Rocco MV, Paranandi L, Burrowes JD et al. Nutritional status in the HEMO Study cohort at baseline. Hemodialysis. Am J Kidney Dis 2002; 39: 245-256.
9. Kloppenburg WD, de Jong PE, Huisman RM. Low calorie intake in dialysis patients: An alternative explanation. Am J Kidney Dis 1999; 33: 1202-1204.
10. Thunberg BJ, Swamy AP, Cestero RV. Cross-sectional and longitudinal nutritional measurements in maintenance hemodialysis patients. Am J Clin Nutr 1981; 34: 2005-2012.
11. Schoenfeld PY, Henry RR, Laird NM et al. Assessment of nutritional status of the National Cooperative Dialysis Study population. Kidney Int Suppl 1983; 13: S80-S88.
12. Wang AY, Sanderson J, Sea MM et al. Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. Am J Clin Nutr 2003; 77: 834-841.
13. Anderstam B, Mamoun AH, Sodersten P et al. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. J Am Soc Nephrol 1996; 7: 2453-2460.
14. McCarthy DO. Tumor necrosis factor alpha and interleukin-6 have differential effects on food intake and gastric emptying in fasted rats. Res Nurs Health 2000; 23: 222-228.
15. Wright M, Woodrow G, O'Brien S et al. Disturbed appetite patterns and nutrient intake in peritoneal dialysis patients. Perit Dial Int 2003; 23: 550-556.
16. Mamoun AH, Anderstam B, Sodersten P et al. Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rats. Kidney Int 1996; 49: 1276-1282.
17. Ikizler TA, Flakoll PJ, Parker RA et al. Amino acid and albumin losses during hemodialysis. Kidney Int 1994; 46: 830-837.
18. Combarnous F, Tetta C, Cellier CC et al. Albumin loss in on-line hemodiafiltration. Int J Artif Organs 2002; 25: 203-209.
19. Lim VS, Kopple JD. Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis. Kidney Int 2000; 58: 1-10.
20. Cano NJ, Aparicio M, Brunori G et al. ESPEN Guidelines on Parenteral Nutrition: Adult renal failure. Clin Nutr 2009; 28: 401-414.
21. Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37: S66-S70.
22. Kalantar-Zadeh K, Ikizler TA. Let them eat during dialysis: An overlooked opportunity to improve outcomes in maintenance hemodialysis patients. J Ren Nutr 2013; 23: 157-163.
23. Kovesdy CP, Shinaberger CS, Kalantar-Zadeh K. Epidemiology of dietary nutrient intake in ESRD. Semin Dial 2010; 23: 353-358.
24. Shinaberger CS, Greenland S, Kopple JD et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 2008; 88: 1511-1518.
25. Kalantar-Zadeh K, Gutekunst L, Mehrotra R et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 519-530.
26. Kloppenburg WD, Stegeman CA, Hovinga TK et al. Effect of prescribing a high protein diet and increasing the dose of dialysis on nutrition in stable chronic haemodialysis patients: A randomized, controlled trial. Nephrol Dial Transplant 2004; 19: 1212-1223.
27. Moe SM, Zidehsarai MP, Chambers MA et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 257-264.
28. Schoenfeld PY, Henry RR, Laird NM et al. Assessment of nutritional status of the national cooperative dialysis study population. Kidney Int 1983; 23: 80-88.
29. Lindsay R, Spanner E, Heidenheim P et al. Which comes first, Kt/V or PCR-Chicken or egg? Kidney Int 1992; 42(Suppl 38): S32-S37.
30. Bergstrom J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int 1993; 43: S39-S50.
31. Davies SJ, Phillips L, Griffiths AM et al. Analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients. Kidney Int 2000; 57: 1743-1754.
32. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
33. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
34. Locatelli F, Martin-Malo A, Hannedouche T et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654.
35. Pierratos A, McFarlane P, Chan CT et al. Daily hemodialysis 2006. State of the art. Minerva Urol Nefrol 2006; 58: 99-115.
36. Chertow GM, Levin NW, Beck GJ et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300.
37. Locatelli F, Manzoni C, Del Vecchio L et al. Recent trials on hemodiafiltration. Contrib Nephrol 2011; 171: 92-100.
38. Bailey JL, Wang X, England BK et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996; 97: 1447-1453.
39. Graham KA, Reaich D, Channon SM et al. Correction of acidosis in hemodialysis decreases whole body protein degradation. J Am Soc Nephrol 1997; 8: 632-637.
40. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-2084.
41. Pickering WP, Price SR, Bircher G et al. Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 2002; 61: 1286-1292.
42. Stein A, Moorhouse J, Iles-Smith H et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997; 52: 1089-1095.
43. Wu DY, Shinaberger CS, Regidor DL et al. Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Clin J Am Soc Nephrol 2006; 1: 70-78.
44. Goldstein SL, Ikizler TA, Zappitelli M et al. Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int 2009; 76: 1063-1069.
45. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol 2005; 16: 2778-2788.
46. Panichi V, Rizza GM, Paoletti S et al. Chronic inflammation and mortality in haemodialysis: Effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337-2343.
47. Niebauer J, Volk HD, Kemp M et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet 1999; 353: 1838-1842.
48. Carrero JJ, Axelsson J, Avesani CM et al. Being an inflamed peritoneal dialysis patient - A Dante's journey. Contrib Nephrol 2006; 150: 144-151.
49. Cordeiro AC, Carrero JJ, Abensur H et al. Systemic and local inflammation in peritoneal dialysis: Mechanisms, biomarkers and effects on outcome. Contrib Nephrol 2009; 163: 132-139.
50. Lopez-Gomez JM, Perez-Flores I, Jofre R et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15: 2494-2501.
51. Aguilera A, Gonzalez-Espinoza L, Codoceo R et al. Bowel bacterial overgrowth as another cause of malnutrition, inflammation, and atherosclerosis syndrome in peritoneal dialysis patients. Adv Perit Dial 2010; 26: 130-136.
52. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: A major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012; 21: 587-592.
53. Cano NJ, Roth H, Aparicio M et al. Malnutrition in hemodialysis diabetic patients: Evaluation and prognostic influence. Kidney Int 2002; 62: 593-601.
54. Deger SM, Sundell MB, Siew ED et al. Insulin resistance and protein metabolism in chronic hemodialysis patients. J Ren Nutr 2013; 23: E59-e66.
55. Siew ED, Ikizler TA. Determinants of insulin resistance and its effects on protein metabolism in patients with advanced chronic kidney disease. Contrib Nephrol 2008; 161: 138-144.
56. Flakoll PJ, Carlson M, Cherrington AC. Physiological action of insulin. In: Leroith DTS, Olefsky J (eds) Diabetes Mellitus: A Fundamental and Clinical Text, 2nd edn. Williams & Wilkins: Philadelpia, PA, 2000; 148-161.
57. Pupim LB, Flakoll PJ, Majchrzak KM et al. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005; 68: 1857-1865.
58. Pupim LB, Heimburger O, Qureshi AR et al. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int 2005; 68: 2368-2374.
59. Siew ED, Pupim LB, Majchrzak KM et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71: 146-152.
60. Grodstein GP, Blumenkrantz MJ, Kopple JD et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19: 564-567.
61. Carrero JJ, Cordeiro AC, Lindholm B et al. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 2010; 19: 37-42.
62. Drechsler C, Krane V, Winkler K et al. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009; 76: 567-575.
63. Qi Y, Takahashi N, Hileman SM et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529.
64. Carrero JJ, Witasp A, Stenvinkel P et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010; 25: 901-906.
65. Kalantar-Zadeh K, Kuwae N, Wu DY et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006; 83: 202-210.
66. de Mutsert R, Snijder MB, van der Sman-de Beer F et al. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007; 18: 967-974.
67. von Haehling S, Lainscak M, Springer J et al. Cardiac cachexia: A systematic overview. Pharmacol Ther 2009; 121: 227-252.
68. Cuppari L, de Carvalho AB, Avesani CM et al. Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism. J Am Soc Nephrol 2004; 15: 2933-2939.
69. Jhamb M, Argyropoulos C, Steel JL et al. Correlates and outcomes of fatigue among incident dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1779-1786.
70. Carrero JJ. Identification of patients with eating disorders: Clinical and biochemical signs of appetite loss in dialysis patients. J Ren Nutr 2009; 19: 10-15.
71. Kimmel PL, Peterson RA, Weihs KL et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000; 57: 2093-2098.
72. Riezebos RK, Nauta KJ, Honig A et al. The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease. Nephrol Dial Transplant 2010; 25: 231-236.
73. Nagler EV, Webster AC, Vanholder R et al. Antidepressants for depression in stage 3-5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant 2012; 27: 3736-3745.
74. Cuppari L, Garcia-Lopes MG. Hypovitaminosis D in chronic kidney disease patients: Prevalence and treatment. J Ren Nutr 2009; 19: 38-43.
75. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92: 131-155.
76. Akmal M, Massry SG, Goldstein DA et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest 1985; 75: 1037-1044.
77. Munoz Mendoza J, Isakova T, Ricardo AC et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 2012; 7: 1155-1162.
78. Veeneman JM, Kingma HA, Boer TS et al. Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am J Physiol Endocrinol Metab 2003; 284: E954-E965.
79. Pupim LB, Majchrzak KM, Flakoll PJ et al. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 2006; 17: 3149-3157.
80. Cockram DB, Hensley MK, Rodriguez M et al. Safety and tolerance of medical nutritional products as sole sources of nutrition in people on hemodialysis. J Ren Nutr 1998; 8: 25-33.
81. Stratton RJ, Bircher G, Fouque D et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: A systematic review and meta-Analysis. Am J Kidney Dis 2005; 46: 387-405.
82. Lacson E Jr., Wang W, Zebrowski B et al. Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: A quality improvement report. Am J Kidney Dis 2012; 60: 591-600.
83. Cheu C, Pearson J, Dahlerus C et al. Association between oral nutritional supplementation and clinical outcomes among patients with ESRD. Clin J Am Soc Nephrol 2012; 8: 100-107.
84. Chertow GM, Ling J, Lew NL et al. The association of intradialytic parenteral nutrition with survival in hemodialysis patients. Am J Kidney Dis 1994; 24: 912-920.
85. Mortelmans AK, Duym P, Vanderbroucke J et al. Intradialytic parenteral nutrition in malnourished hemodialysis patients: A prospective long-term study. JPEN J Parenter Enteral Nutr 1999; 23: 90-95.
86. McCann LM, Foulks CJ. Nutritional recommendations for patients undergoing continous peritoneal dialysis. Semin Dial 1992; 5: 136-141.
87. Cano NJ, Fouque D, Roth H et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: A 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18: 2583-2591.
88. Garibotto G, Sofia A, Canepa A et al. Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure. J Am Soc Nephrol 2001; 12: 557-567.
89. Jones M, Hagen T, Boyle CA et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. Am J Kidney Dis 1998; 32: 761-769.
90. Tjiong HL, van den Berg JW, Wattimena JL et al. Dialysate as food: Combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16: 1486-1493.
91. Kopple JD, Bernard D, Messana J et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47: 1148-1157.
92. Fouque D. Insulin-like growth factor 1 resistance in chronic renal failure. Miner Electrolyte Metab 1996; 22: 133-137.
93. Mehls O, Blum WF, Schaefer F et al. Growth failure in renal disease. Baillieres Clin Endocrinol Metab 1992; 6: 665-685.
94. Haffner D, Schaefer F, Nissel R et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med 2000; 343: 923-930.
95. Mehls O, Wuhl E, Tonshoff B et al. Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr 2008; 97: 1159-1164.
96. Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM et al. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet 1991; 338: 585-590.
97. Ziegler TR, Lazarus JM, Young LS et al. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 1991; 2: 1130-1135.
98. Kopple JD, Brunori G, Leiserowitz M et al. Growth hormone induces anabolism in malnourished maintenance haemodialysis patients. Nephrol Dial Transplant 2005; 20: 952-958.
99. Ikizler TA, Wingard RL, Breyer JA et al. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 1994; 46: 1178-1183.
100. Garibotto G, Barreca A, Russo R et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99: 97-105.
101. Iglesias P, Diez JJ, Fernandez-Reyes MJ et al. Recombinant human growth hormone therapy in malnourished dialysis patients: A randomized controlled study. Am J Kidney Dis 1998; 32: 454-463.
102. Johannsson G, Bengtsson BA, J Ahlmen. Double-blind, placebocontrolled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: Anabolic effect and functional improvement. Am J Kidney Dis 1999; 33: 709-717.
103. Hansen TB, Gram J, Jensen PB et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000; 53: 99-107.
104. Feldt-Rasmussen B, Lange M, Sulowicz W et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18: 2161-2171.
105. Pupim LB, Flakoll PJ, Yu C et al. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 2005; 82: 1235-1243.
106. Guebre-Egziabher F, Juillard L, Boirie Y et al. Short-term administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis. J Clin Endocrinol Metab 2009; 94: 2299-2305.
107. Kopple JD, Cheung AK, Christiansen JS et al. OPPORTUNITY™: A large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant 2011; 26: 4095-4103.
108. Fouque D, Guebre-Egziabher F, Laville M. Advances in anabolic interventions for malnourished dialysis patients. J Ren Nutr 2003; 13: 161-165.
109. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: Review of efficacy and safety. Drugs 2004; 64: 725-750.
110. Bhasin S, Storer TW, Berman N et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1-7.
111. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: Anabolicandrogenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001; 86: 5108-5117.
112. Creutzberg EC, Wouters EF, Mostert R et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003; 124: 1733-1742.
113. Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010; 91: 1143S-1147S.
114. Johns K, Beddall MJ, Corrin RC. Anabolic steroids for the treatment of weight loss in HIV-infected individuals. Cochrane Database Syst Rev 2005; 4: CD005483.
115. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: Potential benefits and risks. J Am Geriatr Soc 2003; 51: 101-115; discussion 15.
116. Gungor O, Kircelli F, Carrero JJ et al. Endogenous testosterone and mortality in male hemodialysis patients: Is it the result of aging? Clin J Am Soc Nephrol 2010; 5: 2018-2023.
117. Carrero JJ, Stenvinkel P. The vulnerable man: Impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant 2012; 27: 4030-4041.
118. Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002; 58: 38-46.
119. Navarro JF, Mora C, Macia M et al. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int 2002; 61: 1537-1544.
120. Gascon A, Belvis JJ, Berisa F et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9: 67-72.
121. Macdonald JH, Marcora SM, Jibani MM et al. Nandrolone decanoate as anabolic therapy in chronic kidney disease: A randomized phase II dose-finding study. Nephron Clin Pract 2007; 106: C125-c135.
122. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 1999; 281: 1275-1281.
123. Kurella Tamura M, Covinsky KE, Chertow GM et al. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 2009; 361: 1539-1547.
124. Leikis MJ, McKenna MJ, Petersen AC et al. Exercise performance falls over time in patients with chronic kidney disease despite maintenance of hemoglobin concentration. Clin J Am Soc Nephrol 2006; 1: 488-495.
125. Ikizler TA, Himmelfarb J. Muscle wasting in kidney disease: Let's get physical. J Am Soc Nephrol 2006; 17: 2097-2098.
126. Kopple JD, Storer T, Casburi R. Impaired exercise capacity and exercise training in maintenance hemodialysis patients. J Ren Nutr 2005; 15: 44-48.
127. Painter P, Johansen KL. Improving physical functioning: Time to be a part of routine care. Am J Kidney Dis 2006; 48: 167-170.
128. Kopple JD, Wang H, Casaburi R et al. Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol 2007; 18: 2975-2986.
129. van den Ham EC, Kooman JP, Schols AM et al. The functional, metabolic, and anabolic responses to exercise training in renal transplant and hemodialysis patients. Transplantation 2007; 83: 1059-1068.
130. Wang XH, Du J, Klein JD et al. Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int 2009; 76: 751-759.
131. Koopman R, van Loon LJ. Aging, exercise, and muscle protein metabolism. J Appl Physiol 2009; 106: 2040-2048.
132. Zinna EM, Yarasheski KE. Exercise treatment to counteract protein wasting of chronic diseases. Curr Opin Clin Nutr Metab Care 2003; 6: 87-93.
133. Cheema B, Abas H, Smith B et al. Progressive exercise for anabolism in kidney disease (PEAK): A randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol 2007; 18: 1594-1601.
134. Dong J, Sundell MB, Pupim LB et al. The effect of resistance exercise to augment long-term benefits of intradialytic oral nutritional supplementation in chronic hemodialysis patients. J Ren Nutr 2011; 21: 149-159.
135. Pupim LB, Flakoll PJ, Levenhagen DK et al. Exercise augments the acute anabolic effects of intradialytic parenteral nutrition in chronic hemodialysis patients. Am J Physiol Endocrinol Metab 2004; 286: E589-E597.
136. Yeh S, Wu SY, Levine DM et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: Correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000; 4: 246-251.
137. Yeh S-S, Marandi M, Thode HC Jr et al. Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexia. J Ren Nutr 2010; 20: 52-62.
138. Ashby DR, Ford HE, Wynne KJ et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 2009; 76: 199-206.
139. Stenvinkel P. Can treating persistent inflammation limit protein energy wasting? Semin Dial 2012; 26: 16-19.
140. Castaneda C, Gordon PL, Parker RC et al. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 2004; 43: 607-616.
141. Cheema BS, Abas H, Smith BC et al. Effect of resistance training during hemodialysis on circulating cytokines: A randomized controlled trial. European journal of applied physiology 2011; 111: 1437-1445.
142. Zhang L, Rajan V, Lin E et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25: 1653-1663.
143. Stubbs JR, Idiculla A, Slusser J et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353-361.
144. Perkins RM, Aboudara MC, Uy AL et al. Effect of pentoxifylline on GFR decline in CKD: A pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009; 53: 606-616.
145. Biolo G, Ciocchi B, Bosutti A et al. Pentoxifylline acutely reduces protein catabolism in chronically uremic patients. Am J Kidney Dis 2002; 40: 1162-1172.
146. Don BR, Kim K, Li J et al. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 2010; 73: 431-438.
147. Hung AM, Ellis CD, Shintani A et al. IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22: 437-442.
148. Lacson E Jr, Ikizler TA, Lazarus JM et al. Potential impact of nutritional intervention on ESRD hospitalization, death and treatment costs. J Ren Nutr 2007; 17: 363-371.
149. Acchiardo S, Moore L, Cockrell S. Effect of essential amino acids (EAA) on chronic hemodialysis (CHD) patients (PTS). Trans Am Soc Artif Intern Organs 1982; 28: 608-614.
150. Allman MA, Stewart PM, Tiller DJ et al. Energy supplementation and the nutritional status of hemodialysis patients. Am J Clin Nutr 1990; 51: 558-562.
151. Tietze IN, Pedersen EB. Effect of fish protein supplementation on aminoacid profile and nutritional status in haemodialysis patients. Nephrol Dial Transplant 1991; 6: 948-954.
152. Eustace JA, Coresh J, Kutchey C et al. Randomized double-blind trial of oral essential amino acids for dialysis-Associated hypoalbuminemia. Kidney Int 2000; 57: 2527-2538.
153. Hiroshige K, Sonta T, Suda T et al. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 2001; 16: 1856-1862.
154. Sharma M, Rao M, Jacob S et al. A controlled trial of intermittent enteral nutrient supplementation in maintenance hemodialysis patients. J Ren Nutr 2002; 12: 229-237.
155. Leon JB, Albert JM, Gilchrist G et al. Improving albumin levels among hemodialysis patients: A community-based randomized controlled trial. Am J Kidney Dis 2006; 48: 28-36.
156. Fouque D, McKenzie J, de Mutsert R et al. Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant 2008; 23: 2902-2910.
157. Moretti HD, Johnson AM, Keeling-Hathaway TJ. Effects of protein supplementation in chronic hemodialysis and peritoneal dialysis patients. J Ren Nutr 2009; 19: 298-303.
158. Guarnieri G, Faccini L, Lipartiti T et al. Simple methods for nutritional assessment in hemodialyzed patients. Am J Clin Nutr 1980; 33: 1598-1607.
159. Cano N, Labastie-Coeyrehourq J, Lacombe P et al. Perdialytic parenteral nutrition with lipids and amino acids in malnourished hemodialysis patients. Am J Clin Nutr 1990; 52: 726-730.
160. Navarro JF, Mora C, Leoaaaan C et al. Amino acid losses during hemodialysis with polyacrylonitrile membranes: Effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables in nondiabetic patients. Am J Clin Nutr 2000; 71: 765-773.
161. Cano NJ, Saingra Y, Dupuy AM et al. Intradialytic parenteral nutrition: Comparison of olive oil versus soybean oil-based lipid emulsions. Br J Nutr 2006; 95: 152-159.